Study Of The Effects Of SB 480848 (Darapladib) On The Electrical Conduction Of The Heart

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This is a study to assess the effects of darapladib on the cardiac conduction of the heart as compared to placebo and moxifloxacin. This a four period crossover design with each period lasting about 10 days. There will be a 7 to 10 day wash out in between each period.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Darapladib; Moxifloxacin

Criteria

Inclusion Criteria:

• Healthy

• Body weight greater than 50 kg (110 lbs) and a body mass index between 19 and 30

• Signed and dated written informed consent prior to admission to the study

• Subject is able to understand and comply with protocol requirements, instructions and protocol-stated restrictions

Exclusion Criteria:

• cardiac abnormalities

• history of asthma or severe allergic reactions

• history of alcohol or drug abuse

• use of prescription or non-prescription drugs or vitamins or herbal supplements

• history of cholecystectomy or biliary tract disease

• pregnant or nursing women

• history of allergy to the study drugs